ClinicalTrials.gg
TerminatedNCT04204252InnovAATeUpdated Aug 12, 2026

Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"

A Phase 3 interventional study of Alpha 1-Antitrypsin and Placebo in Alpha 1-Antitrypsin Deficiency, sponsored by Kamada, Ltd.. Terminated at 9 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Kamada, Ltd. · Phase 3, Interventional, and Treatment

Why this study was terminated
Following interim analysis for futility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.

Enrollment
5th of 25
98 · median 30
Started
2019
the only one that year
Phase 3
7 of 25
1 open now
Registered
22nd of 25
by date
Lead sponsor
1 of 25
Kamada, Ltd.

Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 5th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 3, and was the 22nd registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alpha 1-Antitrypsin

alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD).

The main question it aims to answer is:

  • Can daily treatment with Kamada AAT for inhalation at a dose of 80 mg/day prevent or slow lung function worsening ? Lung function will be measured by spirometry.

Other questions it aims to answer are:

  • Can daily treatment with Kamada AAT for inhalation at a dose of 80 mg/day prevent or slow lung density loss ? Lung density will be measured by a CT scan.
  • Can daily treatment with Kamada AAT for inhalation at a dose of 80 mg/day prevent or slow lung disease from worsening ? Lung disease will be measured using spirometry, lung volume, gas diffusion, six minute walk test, quality of life questionaires and biomarkers.
  • What medical problems do participants have when taking AAT for inhalation 80 mg/day daily ? Researchers will compare AAT for inhalation to a placebo (a look-alike substance that contains no drug) to see if AAT for inhalation works to treat AAT-deficiency related lung disease. Study participants will receive either AAT for inhalation or placebo for the first two years of the study. During the third and fourth years of the study all participants will receive AAT for inhalation regardless of which drug they received during the first two years.

Participants will:

  • Inhale the study drug every day
  • Clean and disinfect the nebulizer every day
  • Document daily symptoms and study drug use in an electronic diary
  • Visit the clinic for tests and assessments. There are 11 clinic visits during the first two years of the study and 5-6 clinic visits during the third and fourth year, combined. After treatment ends, participants will visit the clinic 3 times in half a year.
Read the detailed description

Individuals with a genetic deficiency of alpha-1-antitrypsin (AATD) are at a significantly increased risk (80-100%) of developing lung disease (emphysema or COPD). This study is designed to administer a solution of AAT by nebulizer so that patients can inhale the drug instead of requiring infusions as in current treatment. A significant advantage of inhalation is that the AAT is directly transferred to the lungs, which is the site most in need of the protein. Previous results show that in addition to the added convenience, treatment restores normal levels of active AAT to the lung. To date, more than 220 participants have completed clinical trials with AAT for inhalation for several diseases.

03

Conditions studied

  • Alpha 1-Antitrypsin Deficiency

Keywords

  • Alpha 1 Antitrypsin
  • Inhaled Alpha 1 Antitrypsin
  • Nebulizer
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of severe AAT deficiency, i.e. patients with either Pi(ZZ), Pi(Z/Null), or Pi(Null/Null) genotypes.
  2. Serum AAT levels ≤ 11 µM at screening.
  3. Lung disease with clinical evidence of airflow limitation (post bronchodilator /SVC≤70%) at screening.
  4. 40% ≤ FEV1 ≤ 80% of predicted post-bronchodilator at screening.
  5. Patients who are either naïve or washed out of any AAT treatment for at least 8 weeks prior to randomization.
  6. Age between 18 to 65 years inclusive at screening.
  7. Able to read and sign and willing to participate in the study.
  8. Males or non-pregnant, non-lactating females whose screening pregnancy test is negative, who are willing to use methods for the duration of the study, or who are , or surgically sterilized.
  9. Study medication use for at least 20 out of the 28 days of run-in, as recorded in the study nebulization PARI Track data.
  10. Demonstrated ability to complete eDiary for at least 20 out of the first 28 days of run-in.

Exclusion criteria

Exclusion Criteria

  1. Immunoglobulin A (IgA) absolute deficiency defined as serum IgA levels \< 0.05 g/L.
  2. History of life-threatening transfusion reaction(s), allergy, anaphylactic reaction, or systemic response to human plasma-derived products.
  3. Two or more moderate or any severe exacerbation(s) within the year prior to baseline.
  4. A moderate exacerbation within 6 weeks prior to baseline.
  5. Use of oral or parenteral in doses above 10 mg of prednisone daily or equivalent generics (substance and dose).
  6. inter-current illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal, or other. Patients might be included after consultation with the treating physician and the sponsor if, in the opinion of the Investigator, their condition will not interfere with the safety, compliance or other aspects of this study.
  7. Hospitalization for any cause during the 6 weeks prior to screening.
  8. History of lung or liver transplant.
  9. On any thoracic or hepatic surgery waiting list.
  10. Any lung surgery within the past two years (including bronchoscopic lung volume reduction).
  11. Any smoking within the year prior to screening.
  12. Evidence of alcohol abuse or history of alcohol abuse, or use of illegal drugs and/or abuse of legally prescribed drugs in the last 5 years prior to screening.
  13. Acute or chronic hepatitis (hepatitis A, , ), or positive (HIV) serology.
  14. Signs of significant abnormalities in serum hematology, serum chemistry, serum inflammatory / immunogenic markers and urinalysis per investigator judgment, taking into considerations the potential effects of the AAT deficiency.
  15. Signs of significant abnormalities in per investigator judgment at screening.
  16. Presence of psychiatric/ mental disorder or any other medical disorder that might impair the patient's ability to give or to comply with the requirements of the study protocol. If, in the opinion of the Investigator, the condition will not interfere with the compliance or other aspects of this study, the patient might be included after consultation with the treating physician and the sponsor.
  17. Participation in another clinical trial involving medication or interventional treatment within 30 days and/or last dose 5 half-lives prior to screening visit.
  18. Inability to attend scheduled clinic visits and/or comply with study protocol.
  19. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol.

Additional eligibility criteria apply for the open label extension

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Active comparator
    Inhaled AAT

    Daily inhalation of 80 mg/day "Kamada-AAT for Inhalation" for 104 weeks

    Drug: Alpha 1-Antitrypsin

  • Placebo comparator
    Placebo

    Daily inhalation of a solution of NaCl in phosphate buffer solution with 0.01% TWEEN-80

    Drug: Placebo

Interventions

  • Kamada's alpha 1-antitrypsin product given by inhalation using the eFlow® electronic nebulizer manufactured by PARI Pharma GmbH

    Also known as: Kamada alpha 1-antitrypsin for inhalation

  • DrugPlacebo

    Preparation of NaCl in phosphate buffer solution with 0.01% TWEEN-80

06

What researchers measure

Primary outcomes

  1. FEV1 post bronchodilator

    Change from baseline in post bronchodilator FEV1 at 104 weeks

    Time frame: 104 weeks

Secondary outcomes

  1. CT densitometry whole-lung 15th percentile lung density (PD15) at total lung capacity (TLC).

    Change from baseline over 104 weeks of treatment in CT densitometry whole-lung 15th percentile lung density (PD15) at total lung capacity (TLC).

    Time frame: 104 weeks

  2. FEV1 % of predicted

    Change from baseline over 104 weeks of treatment in FEV1 % of predicted

    Time frame: 104 weeks

  3. FEV1/FVC %

    Change from baseline over 104 weeks of treatment in FEV1/FVC %

    Time frame: 104 weeks

  4. Exacerbations

    Annual rate of exacerbations by severity and duration

    Time frame: 104 weeks

  5. 6 minute walk test

    Change from Baseline in the distance walked in six minutes

    Time frame: 104 weeks

Other outcomes

  1. TEAEs

    Rate and severity of adverse events during treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs) and serious adverse events (SAEs) during treatment and follow-up period \[Safety Outcome\]

    Time frame: 130 weeks

  2. PiM

    Plasma M-type AAT specific (PiM) levels evaluated as function of exposure time, antibody response (positive vs. negative), and antibody titers. \[Safety Outcome\]

    Time frame: 130 weeks

  3. ADA/nADA

    Rate and titers of binding and neutralizing AAT antibodies (ADA/nADA) in plasma \[Safety Outcome\]

    Time frame: 130 weeks

  4. ECG

    Electrocardiogram \[Safety Outcome\] will be classified as normal or abnormal.

    Time frame: 130 weeks

07

Study locations

9 sites
  • University Hospital (UZ) Leuven
    Leuven, Belgium
  • Tays Central Hospital
    Tampere, Finland
  • Beaumont Hospital
    Dublin, D09 YD60, Ireland
  • Leiden University Medical Center (LUMC)
    Leiden, ZA 2333ZA, Netherlands
  • Canisius Wilhelmina Hospital (CWZ)
    Nijmegen, 6532SZ, Netherlands
  • Skåne University Hospital
    Malmö, SE-20502, Sweden
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B15 2GW, United Kingdom
  • Royal Infirmary of Edinburgh
    Edinburgh, EH16 4SA, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, SO16 6YD, United Kingdom
08

References and documents

Publications

  • Kappe NN, Alagem N, Tov N, Stolk J. Governmental Non-Pharmaceutical Interventions during the COVID-19 Pandemic and the COPD Exacerbation and Respiratory Infection Rate in Patients with Alpha-1 Antitrypsin Deficiency. COPD. 2023 Dec;20(1):292-297. doi: 10.1080/15412555.2023.2249108. PubMed 37665565 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Feb 2026, 74 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2019
First posted
Dec 18, 2019
StartActual
Nov 25, 2019
Primary completionActual
Feb 19, 2026
CompletionActual
Feb 27, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04204252
Lead sponsor
Kamada, Ltd.
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Dec 18, 2019
Start date
Nov 25, 2019
Primary completion
Feb 19, 2026
Completion
Feb 27, 2026
Last update
Aug 12, 2026

Study contacts

Jan Stolk, Prof
principal investigator · LUMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion